Citius Pharmaceuticals (NASDAQ: CTXR) stock went down on Tuesday after a 15% jump in the past week. The stock has been in a nice uptrend since the beginning of the year with a jump of over 120%. The stock is now trading 24% away from its 52-week high of $2.90.
Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting
- CTXR announced that it has received the Best Poster Award at the prestigious International Society for Cell and Gene Therapy (ISCT) 2021 Annual Meeting.
- The poster, titled “Novel Induced-Mesenchymal Stem Cells (i-MSCs) Attenuate Severity of ARDS in Septic Sheep,” will be presented today, May 25, 2021 by Dr. Perenlei Enkhbaatar, Professor and Director of the Translational Intensive Care Unit at The University of Texas Medical Branch.
“The ISCT annual meeting brings together the brightest minds in cell and gene therapy and highlights cutting edge research in the field,” stated Dr. Myron Czuczman, Chief Medical Officer and Executive Vice President of Citius.
Myron Holubiak, President and Chief Executive Officer of Citius added, “We are grateful to be recognized by our peers for this award as we advance our novel stem cell program for the treatment of ARDS. In parallel to the expansion of our proof-of-concept ARDS sheep study, we are following guidance from the U.S. Food and Drug Administration (FDA) in the development of a cGMP Master Cell Bank of i-MSCs.
On Tuesday, CTXR stock fell 6 cents or 2.63% to close at $2.22. More than 2.91 million shares traded hands for the session, compared to its 30-day average volume of 7.49 million shares. The stock opened at $2.95 and moved within a wide range of $2.2100 – 2.3400 on Tuesday.